Centene (CNC)
(Delayed Data from NYSE)
$57.46 USD
-1.22 (-2.08%)
Updated Nov 15, 2024 04:00 PM ET
After-Market: $57.43 -0.03 (-0.05%) 7:58 PM ET
3-Hold of 5 3
A Value F Growth C Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$57.46 USD
-1.22 (-2.08%)
Updated Nov 15, 2024 04:00 PM ET
After-Market: $57.43 -0.03 (-0.05%) 7:58 PM ET
3-Hold of 5 3
A Value F Growth C Momentum C VGM
Zacks News
Could April be a Better Month for Stocks? 5 Large-Cap Picks
by Swarup Gupta
Historical data shows that the Dow has gained 1.9% on average during April since 1950.
Seagate Technology, Cadence Design Systems, NVIDIA, Micron and Centene highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Seagate Technology, Cadence Design Systems, NVIDIA, Micron and Centene highlighted as Zacks Bull and Bear of the Day
Time to Learn from the Facts: Global Week Ahead
by Mark Vickery
Bond market economists and stock strategists alike consider the huge flow of macro data out in the first week of a month ??? particularly payrolls in the USA, inflation in Europe, and manufacturing PMIs everywhere ??? to be catalysts for changes to their quarterly and annual outlooks, on rates and on stock prices, respectively.
Zacks.com highlights: Pioneer Natural Resources, Centene, Mammoth Energy Services, Stoneridge and FTI Consulting
by Zacks Equity Research
Zacks.com highlights: Pioneer Natural Resources, Centene, Mammoth Energy Services, Stoneridge and FTI Consulting
The Zacks Analyst Blog Highlights: Facebook, Centene, Nitto Denko and TIM Participacoes SA
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Facebook, Centene, Nitto Denko and TIM Participacoes SA
Here's Why You Should Steer Clear of DENTSPLY (XRAY) for Now
by Zacks Equity Research
DENTSPLY SIRONA (XRAY) faces foreign exchange woes and chances of margin decline in the quarters ahead.
Enhance Your Returns With 5 Relative Price Strength Stocks
by Nilanjan Choudhury
Want to try an out-of-the-box approach to earn handsome returns? Tap these stocks with explosive relative price strength.
More Angst About Facebook: Global Week Ahead
by John Blank
It looks like a quiet Global Week Ahead. This happens towards the end of any month. These are, for the most part, a continuation of worries that surfaced in recent weeks. Nothing is 'new' news.
Zacks.com featured highlights include: Dine Brands, Builders FirstSource, Centene, Encore Wire and HFF
by Zacks Equity Research
Zacks.com featured highlights include: Dine Brands, Builders FirstSource, Centene, Encore Wire and HFF
5 Best Momentum Stocks to Buy Using Driehaus Strategy
by Zacks Equity Research
Investors with a high risk appetite might give the Driehaus strategy a thought to boost returns.
New Strong Buy Stocks for March 21st
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Wednesday
5 Reasons Why Centene is an Attractive Bet for Investors
by Zacks Equity Research
Centene (CNC) can be considered a lucrative investment option on the back of top-line growth, inorganic strategies and a solid financial health.
Should Value Investors Pick Centene Corporation (CNC) Stock?
by Zacks Equity Research
Let's put Centene Corporation (CNC) stock into this equation and find out if it is a good choice for value-oriented investors right now.
Centene Makes Investment in RxAdvance, Builds Partnership
by Zacks Equity Research
Centene's (CNC) transformative alliance with RxAdvance is another instance of Health insurers joining forces with pharmacy benefit managers to reduce the costs in the drug supply chain.
Cigna on Raters' Radar After Express Scripts Bid, Stock Down
by Zacks Equity Research
Cigna (CI) gets rating downgrade on a number of concerns related to the Express Scripts deal.
5 Top Stocks to Make the Most of March Madness
by Tirthankar Chakraborty
March Madness tournaments mostly concur with strong stock gains. The phenomenon starts from the second week of March and lasts through the first week of April.
Shrug Off Market Gyrations With These Top 5 Value Picks
by Zacks Equity Research
Despite a recovery from recent correction, several concerns plague the investors. A global trade war, hike in interest rate and an inflationary tendency in the U.S. economy are major near-term concerns.
Why Is Centene (CNC) Down 2.6% Since its Last Earnings Report?
by Zacks Equity Research
Centene (CNC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
The Zacks Analyst Blog Highlights: Centene, Macy's, LyondellBasell, Huntington Ingalls and Lam Research
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Centene, Macy's, LyondellBasell, Huntington Ingalls and Lam Research
3 Reasons Why You Should Invest in athenahealth (ATHN) Stock
by Zacks Equity Research
athenahealth (ATHN) rides on solid fourth-quarter results and strong fundamentals.
Are Tariff War Fears Overblown? 5 Great Value Choices
by Swarup Gupta
Trump's NAFTA related comments show that the President is yet to make up his mind on tariff-related announcements.
ResMed (RMD) Rides High on Robust Global Growth & Innovation
by Zacks Equity Research
ResMed (RMD) consistently invests and expands globally in high-growth markets like China, South Korea, India, Brazil and across the Eastern Europe belt.
Varian (VAR) Rides on Diverse Product Line, Competition Rife
by Zacks Equity Research
Varian Medical (VAR) has a strong international presence and growing proton therapy market. However, intense competition adds to woes.
Stryker Closes Entellus Buyout, Bolsters Neurotechnology Line
by Zacks Equity Research
Stryker (SYK) maintains its acquisition-driven strategy to provide superior and more economic patient experiences.
Cardiovascular Systems Gains From 510K for OrbusNeich Device
by Zacks Equity Research
Cardiovascular Systems (CSII) to distribute limited editions of both 1.0-4.0mm Sapphire II PRO and 2.0-4.0mm Sapphire NC Plus non-compliant coronary balloons post the product launches in the market.